Predict your next investment

FINANCIAL
aciesinc.com

See what CB Insights has to offer

Founded Year

2004

Stage

Unattributed VC | Alive

Total Raised

$500K

Last Raised

$500K | 17 yrs ago

About Acies

Acies is a Financial company based in New York, New York. Acies has received investment from Life Sciences Greenhouse of Central Pennsylvania.

Acies Headquarter Location

132 West 36th Street 3rd Floor

New York, New York, 10018,

United States

212-931-5180

Latest Acies News

Acies wins the 2021 Asia Risk 'Risk Management Consultant of the Year' award

Sep 28, 2021

PRNewsWire India MUMBAI, India and SINGAPORE and HONG KONG, Sept. 27, 2021 /PRNewswire/ -- Acies was awarded the 'Risk Management Consultant of the Year' for its work with more than 15 Indian insurance companies and global banks on interest rate risk management. The Asia Risk Awards 2021 virtual ceremony of Acies' award was held on 27 September 2021. As demand for savings and annuity products increased significantly amid falling interest rates during the pandemic, Acies, headquartered in India's financial hub of Mumbai, acted swiftly in helping its insurance clients manage interest rate risk. It achieved this with an extensive suite of strategies, processes and technology. "We worked with some large banks with an intention of coming up with an industry solution that would allow insurers to de-risk the interest rate guarantee they give to the end-users," says Muzammil Patel, Managing Director at Acies.Acies also engaged with banking and insurance regulators to address concerns, modify product structures and enable a standardised roll-out to the industry to ensure responsible and sustainable growth of the forward rate agreement (FRA) product. Acies' work brought about transparency and standardisation in FRA pricing and valuation.For insurance clients, Acies provides end-to-end consulting services - including setting up risk management and accounting frameworks, and a derivatives system. The derivatives system, Kore considers transaction entries, daily mark-to-market updates, daily margining and, subsequently, ledger entries to be passed onto the accounting system. Finally, Acies' solutions also help generate risk measures that must be submitted to regulators. "We want to make sure the insurers are working on a fully-hedged basis; that they are accounting for derivatives correctly and they can prove to the regulators they have the requisite offsets and risk capital," says Muzammil Patel. "When that happens, it gives them more latitude to de-risk the entire spectrum. "To know more about this award, visit https://www.risk.net/awards/7873981/risk-management-consultant-of-the-year-aciesAbout the Asia Risk AwardsThe Asia Risk Awards, hosted by Risk.Net is the longest-running and most prestigious awards for firms and individuals involved in the Asia's derivatives markets and in risk management.For a full list of award winners, visit https://www.asiariskcongress.com/awards. About Acies Acies is a multi-national firm comprising businesses focussed on providing technology applications and platforms, consulting, content and learning and development solutions, and strategic investments. implement, skill and scale businesses to support growth and sustainability.To know more about Acies, visit https://www.acies.consulting or the LinkedIn Company page. Advertisements

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Acies Patents

Acies has filed 6 patents.

The 3 most popular patent topics include:

  • Autosomal recessive disorders
  • Antibiotics
  • Genetic diseases and disorders
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/23/2015

4/21/2020

Statins, Carboxylic acids, Fluoroarenes, Diols, Hypolipidemic agents

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/23/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

4/21/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Statins, Carboxylic acids, Fluoroarenes, Diols, Hypolipidemic agents

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.